Literature DB >> 19584744

Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance.

Paul W X Foley1, Malcolm S Hamilton, Francisco Leyva.   

Abstract

We present the case of a 60-year-old lady who was treated with chemotherapy for myeloma. Following initiation of bortezomib, she developed heart failure which was associated with a reduction in left ventricular systolic function. A gadolinium enhanced cardiovascular magnetic resonance scan demonstrated midwall hyperenhancement consistent with midwall fibrosis.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19584744     DOI： 10.2459/JCM.0b013e32832f3ff2

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN： 1558-2027            Impact factor:   2.160


  12 in total

1.  Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma.

Authors:  Hiroyuki Takamatsu; Takeshi Yamashita; Takeharu Kotani; Aiko Sawazaki; Hirokazu Okumura; Shinji Nakao
Journal:  Int J Hematol       Date:  2010-05-11       Impact factor: 2.490

2.  Myocardial strain pattern in patients with cardiac amyloidosis secondary to multiple myeloma: a cardiac MRI feature tracking study.

Authors:  Sabha Bhatti; Srikanth Vallurupalli; Stephanie Ambach; Adam Magier; Evan Watts; Vien Truong; Abdul Hakeem; Wojciech Mazur
Journal:  Int J Cardiovasc Imaging       Date:  2016-10-14       Impact factor: 2.357

Review 3.  Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies.

Authors:  Oliver Drews; Heinrich Taegtmeyer
Journal:  Antioxid Redox Signal       Date:  2014-10-01       Impact factor: 8.401

Review 4.  Cardiovascular Imaging in Cardio-Oncology: The Role of Echocardiography and Cardiac MRI in Modern Cardio-Oncology.

Authors:  John Alan Gambril; Aaron Chum; Akash Goyal; Patrick Ruz; Katarzyna Mikrut; Orlando Simonetti; Hardeep Dholiya; Brijesh Patel; Daniel Addison
Journal:  Heart Fail Clin       Date:  2022-07       Impact factor: 2.828

5.  Mid wall fibrosis on CMR with late gadolinium enhancement may predict prognosis for LVAD and transplantation risk in patients with newly diagnosed dilated cardiomyopathy-preliminary observations from a high-volume transplant centre.

Authors:  Jose V Venero; Mark Doyle; Moneal Shah; Vikas K Rathi; June A Yamrozik; Ronald B Williams; Diane A Vido; Geetha Rayarao; Raymond Benza; Srinivas Murali; Jerry Glass; Peter Olson; George Sokos; Robert W W Biederman
Journal:  ESC Heart Fail       Date:  2015-07-29

6.  Bortezomib-Induced Reversible Cardiomyopathy: Recovered With Guideline-Directed Medical Therapy.

Authors:  Swethika H Sundaravel; Rosalyn I Marar; Muhannad A Abbasi; Muhamed Baljevic; Jeremy R Stone
Journal:  Cureus       Date:  2021-12-09

7.  Cardiovascular-specific mortality among multiple myeloma patients: a population-based study.

Authors:  Xuejiao Yin; Fengjuan Fan; Bo Zhang; Yu Hu; Chunyan Sun
Journal:  Ther Adv Hematol       Date:  2022-03-31

8.  Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity.

Authors:  Sachin Diwadkar; Aarti A Patel; Michael G Fradley
Journal:  Case Rep Cardiol       Date:  2016-01-28

Review 9.  Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).

Authors:  Sara Bringhen; Alberto Milan; Claudio Ferri; Ralph Wäsch; Francesca Gay; Alessandra Larocca; Marco Salvini; Evangelos Terpos; Hartmut Goldschmidt; Michele Cavo; Maria Teresa Petrucci; Heinz Ludwig; Holger W Auner; Jo Caers; Martin Gramatzki; Mario Boccadoro; Hermann Einsele; Pieter Sonneveld; Monika Engelhardt
Journal:  Haematologica       Date:  2018-07-26       Impact factor: 9.941

10.  Increased Prevalence of Fragmented QRS in Randomly Selected Group of Multiple Myeloma Patients: A Pilot Study to Assess Prevalence.

Authors:  Angel López-Candales; Fuad Habash; Srikanth Vallurupalli
Journal:  Cureus       Date:  2021-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.